IL1B and cancer: Extensive research in the last few decades has revealed that cancer develops as a consequence of dysregulation of several signaling pathways leading to increased expression of EGFR, cyclooxygenase-2 (COX-2), nuclear factor (NF)-κB, interleukin (IL)-6, and IL-1, prostaglandins, cyclin D1 and cyclin E (cell cycle proteins), vascular endothelial growth factor (VEGF), matrix metalloproteinases (invasion-promoting proteins), Bcl-2, Bcl-XL, survivin, and XIAP (cell survival proteins), cMyc, and AP-1 (cellular proliferation) [13].